Supreme Court’s Consideration Of ACA’s “Individual Mandate” Has Three Possible Outcomes
This article was originally published in The Pink Sheet Daily
Executive Summary
At stake is the requirement for individuals to purchase health insurance and whether that provision is severable from the rest of the Affordable Care Act. From the pharmaceutical industry’s perspective, the most disruptive outcome would be to have the entire law overturned.
You may also be interested in...
Voices From The Bench: Supreme Court Justices Probe The Affordable Care Act
“The Pink Sheet” highlights intriguing, and perhaps telling, comments by U.S. Supreme Court justices from three days of oral arguments pertaining to the constitutionality of the Affordable Care Act, including the constitutionality of the “individual mandate” for insurance coverage, its severability from other ACA provisions, and whether new Medicaid requirements are an unconstitutional coercion of the states.
Patient Assistance Programs Will Still Have Role In Post Health Care Reform World – Covance Exec
PAPs will have place even assuming the Affordable Care Act survives Supreme Court review, Covance’s Greg Hall says. Key factors include whether government subsidized individuals remain eligible for PAP aid and to what extent employers drop insurance coverage.
CMS Administrator-Nominee Tavenner Would Bring Leadership Continuity As ACA Implementation Continues
With the selection of Centers for Medicare and Medicaid Services Principal Deputy Administrator Marilyn Tavenner as Don Berwick’s successor, the Obama administration appears to be seeking leadership continuity with a candidate that has a good chance of gaining Senate confirmation.